|
|
Welcome to
the ISOPP Website
Thanks to our Sponsors
Cochrane review: Adjuvant Therapy for completely resected Stage II Colon Cancer
By: Felice Musicco
on: Fri 04 of Jul, 2008 [13:03 UTC]
(8 reads)
|
|
Authors' conclusions
Although there was no improvement in overall survival in the pooled analysis, we did find that disease-free survival in patients with stage II colon cancer was significantly better with the use of adjuvant therapy.
|
New NICE guidance about cancer
By: Felice Musicco
on: Wed 02 of Jul, 2008 [10:44 UTC]
(20 reads)
|
|
Breast cancer (advanced & metastatic) - bevacizumab (terminated appraisal)
Colorectal cancer (metastatic) - cetuximab (terminated appraisal)
Glioma (recurrent) - carmustine implants (terminated appraisal)
Head and neck cancer - cetuximab
Lung cancer (non-small-cell) - bevacizumab (terminated appraisal)
News received by Rolando Moroni
|
EMEA Updated safety information for lenalidomide
By: Felice Musicco
on: Mon 30 of Jun, 2008 [12:36 UTC]
(31 reads)
|
|
The CHMP recommended updating the product information of Revlimid (lenalidomide) from Celgene Europe Ltd with results from a nonclinical study. These results show that lenalidomide is teratogenic in monkeys. Lenalidomide is therefore expected to be teratogenic in humans.
|
EMEA recommends a new warning for epoetins for their use in cancer patients
By: Felice Musicco
on: Fri 27 of Jun, 2008 [02:07 UTC]
(39 reads)
|
|
The European Medicines Agency (EMEA) has recommended updating the product information for epoetin-containing medicines with a new warning for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patients suffering cancer. Epoetin-containing medicines are indicated in patients with chronic renal failure and for the treatment of anaemia in symptomatic patients with non-myeloid tumours receiving chemotherapy.
|
ISOPP/HOPA 2008: Abstracts Platform Presentations
By: Felice Musicco
on: Thu 26 of Jun, 2008 [13:46 UTC]
(68 reads)
|
|
Journal Of Oncology Pharmacy Practice June 2008, Volume 14, No. 2
|
EMEA Extensions of indication for cetuximab and human papilloma virus vaccine
By: Felice Musicco
on: Wed 25 of Jun, 2008 [23:27 UTC]
(37 reads)
|
|
The CHMP adopted three positive opinions by consensus on applications for extension of indication, adding new treatment options for Erbitux (cetuximab), from Merck KGaA and Gardasil (human papilloma virus vaccine), from Sanofi Pasteur MSD, and Silgard (human papilloma virus recombinant vaccine), from Merck Sharp & Dohme.
|
Azacitidine in High Risk MDS - Improved Overall Survival
By: Helen Leather
on: Sun 22 of Jun, 2008 [13:28 UTC]
(51 reads)
|
|
A sub-analysis was reported of a previously reported large, randomized phase III study (AZA-001), which showed that treatment with VIDAZA (azacitidine) prolonged overall survival for patients with high-risk myelodysplastic syndromes (MDS) when compared to conventional care regimens (CCR). This analysis evaluated a sub-group of patients (n=94) who were pre-selected to receive low dose Ara-C, a chemotherapy used in the treatment of MDS and acute myeloid leukemia (AML). The results confirm that the significant survival benefit originally reported with VIDAZA in the overall population was also seen when VIDAZA was directly compared to the active comparator arm of low dose Ara-C. The data were presented at the 13th European Hematology Association (EHA) Congress in Copenhagen, Denmark.
|
Multilingual Glossary of technical and popular medical terms in nine Languages
By: Felice Musicco
on: Wed 11 of Jun, 2008 [00:34 UTC]
(113 reads)
|
|
This project was commissioned by The EuropeanCommission(DG III) and executed by Heymans Institute of Pharmacology and Mercator School, Department of applied Linguistics. University of Gent, De Pintelaan 185, B-9000 Gent (BE)
|
FDA Early Communication About an Ongoing Safety Review of TNF Blockers
By: Felice Musicco
on: Mon 09 of Jun, 2008 [15:52 UTC]
(126 reads)
|
|
FDA is investigating the possible association between the use of medicines known as tumor necrosis factor (TNF) blockers and the development of lymphoma and other cancers in children and young adults. These individuals were treated with TNF blockers for Juvenile Idiopathic Arthritis (JIA), Crohn’s disease or other diseases. News received by Rolando Moroni.
|
Reporting the findings of clinical trials: WHO online survey
By: Felice Musicco
on: Sat 07 of Jun, 2008 [02:58 UTC]
(129 reads)
|
|
The WHO Registry Platform Working Group on the Reporting of Findings of Clinical Trials have proposed that “the findings of all clinical trials must be made publicly available”. On 20th May an online survey commenced, the aim of which is to obtain feedback on this proposed position.
To participate in the survey please "read more"
|
|
ISOPP HOPA 2008
Click on the Logo above to link to the ISOPP/HOPA
symposium page
|
